Journal article
The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder
OS Schwartz, P Amminger, BT Baune, G Bedi, M Berk, SM Cotton, R Daglas-Georgiou, N Glozier, B Harrison, DF Hermens, E Jennings, J Lagopoulos, C Loo, S Mallawaarachchi, D Martin, B Phelan, N Read, A Rodgers, L Schmaal, AA Somogyi Show all
Trials | BMC | Published : 2023
Abstract
Background: Existing treatments for young people with severe depression have limited effectiveness. The aim of the Study of Ketamine for Youth Depression (SKY-D) trial is to determine whether a 4-week course of low-dose subcutaneous ketamine is an effective adjunct to treatment-as-usual in young people with major depressive disorder (MDD). Methods: SKY-D is a double-masked, randomised controlled trial funded by the Australian Government’s National Health and Medical Research Council (NHMRC). Participants aged between 16 and 25 years (inclusive) with moderate-to-severe MDD will be randomised to receive either low-dose ketamine (intervention) or midazolam (active control) via subcutaneous inje..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The authors would like to acknowledge the Orygen Sponsor Operations Department for their assistance and guidance in the preparation of the SKY-D protocol.